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Abstract
Background: To report the results of combined chemoradiation (CCRT) with cisplatin versus carboplatin in locally
advanced cervical carcinoma.
Methods: From 2009 to 2013, 255 patients with stage IIB-IVA cervical carcinoma, according to FIGO staging were
prospectively assigned to be treated with pelvic radiotherapy followed by brachytherapy given concurrently with
cisplatin or carboplatin in the treatment of locally advanced cervical cancer. Treatment outcomes and toxicitiy were
evaluated.
Results: Two-hundred and thirteen patients could be evaluated. At a median follow-up time of 43 months (6–69
months), the 3-year local control, disease-free survival, metastasis-free survival and overall survival rates were 93, 80.8,
85.0 and 87.3 %, respectively. No statistical difference in terms of local control, disease-free survival, metastasis-free
survival and overall survival rates between cisplatin and carboplatin treatments was observed in this study. Eighty-six
percents of the patients in the carboplatin group could receive more than 4 cycles, while there were only 72 % in the
cisplatin group who completed more than 4 cycles (p = 0. 02). In terms of acute toxicity, cisplatin caused significantly
more anemia (p = 0.026), neutropenia (p = 0. 044) and nephrotoxicity (p = 0. 031) than carboplatin. No difference in late
toxicity was observed in this study.
Conclusion: Carboplatin yielded comparable results to cisplatin in concurrent chemo-radiation for locally advanced
cervical cancer. In addition, carboplatin was associated with a better compliance rate and was associated with less of
anemia, neutropenia and nephrotoxicity.
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Backgrounds
Cervical carcinoma is one of the most frequent cancer
entities in Northern Thailand. According to the report
of Kamnerdsupaphon et al. the age-standardized inci-
dence rate22.7 per 100,000 and there were 234 new
cases of cervix cancer diagnosed in 2005 and was one of
the three most common cancers in female. Moreover, it
ranked second after breast cancer [1]. The treatment
options of cervical cancer are composed of surgery,
radiotherapy and/or chemotherapy according to stage
and performance status of patients. For locally advanced
disease, pelvic radiation and brachytherapy given con-
currently with a platinum-based regimen is the standard
treatment [2–4].
Weekly cisplatin is the most commonly used regi-
men for chemoradiation. However, it may cause acute
toxicities, including nephrotoxicity and ototoxicity [5].
The comparative data between cisplatin and carboplatin
were generally assessed in metastatic disease and mostly in
phase II or retrospective studies [6–8]. In locally advanced
cervical cancer, no prospective study has compared out-
comes and treatment related toxicities between the two
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types of chemotherapy. One retrospective study on
cisplatin versus carboplatin for concurrent chemoradi-
ation for locally advanced cervical cancer reported
carboplatin did not showed benefits over cisplatin [9].
To our knowledge, there were many published studies
that reported the experiences of concurrent carbopla-
tin [10–15]. In our center, carboplatin has been used
for patients with poor functional status or age >70 or
any age with poor creatinine clearance. The question
of using carboplatin in good performance status needs
to be answered. We performed this observational
study to evaluate prospectively the disease-related
outcomes and therapy –related toxicity of cisplatin
versus carboplatin in concurrent chemoradiation for
patients with locally advanced cervical cancer.
Methods
Patients
Two-hundred and fifty five patients with biopsy proven cer-
vical cancer were included in this study from February
2009 to February 2013. All enrolled cervical cancer patients
were classified as IIB-IVA by FIGO clinical staging, were
18–70 years old at study entry and had a Karnofsky per-
formance status > 70 %. All patients had normal laboratory
results with hemoglobin (Hb) ≥10 g/dl, white blood count
(WBC) ≥3000 cells/mm3, platelet count ≥ 100,000 cells/
mm3, serum creatinine clearance ≥50 ml/min and normal
liver function tests.
Patients with a severe co-morbidity, pregnancy, previ-
ous radiotherapy, distant metastases at diagnosis or his-
tory of allergies were excluded from the study.
This study was approved by the Ethic committee of
faculty of medicine, Chiang Mai University with the
study code of RAD-08-12-12A-13. This study was
performed in accordance with the principles of human
clinical trials and the Helsinki Declaration (1975 edition
and 2000 revised edition). All of the patients signed
informed consent before treatment.
Radiotherapy techniques
Radiotherapy for cervical cancer in our institution is
performed in concordance with the publication by
Lorvidhaya et al. [16].
Whole pelvic radiotherapy (WPRT)
All patients received WPRT to the primary tumor
and pelvic lymph nodes by conventional radiotherapy
to the total dose of 50 Gy in 25 fractions. After
44 Gy, central shielding was conventionally added to
reduce the bladder and rectal dose. After 50 Gy,
Fig. 1 Treatment schema
Table 1 Patient characteristics by study groups
Parameters cisplatin (N = 137) carboplatin (N = 76) P-value
Age (years) 51.6 (21–67) 53.8 (35–70) 0.051
Maximal diameter of
primary tumor(cm)
4.5 (2–8) 4.3(2–9) 0.4
Stage 0.09
IIB 91(66.4 %) 43(56.6 %)
IIIA 0 2(2.6 %)
IIIB 44(32.1 %) 31(40.8 %)
IVA 2(1.5 %) 0
Pelvic Lymph nodes 0.63
No 72(52.6 %) 45(59.2 %)
Yes 14(10.2 %) 6(7.9 %)
Unknown 51(37.2 %) 25(32.9 %)
Histology 0.4
SCCA 114(83.2 %) 66(86.8 %)
ACA 21(15.3 %) 9(11.8 %)
Others 2(1.5 %) 1(1.3 %)
Histologic grade 0.66
1 18(14.8 %) 9(13.4 %)
2 78(63.9 %) 47(70.1 %)
3 26(21.3 %) 11(16.4 %)
Cycles 0.02
Up to 4 cycles 38 (27.7 %) 10(13.2 %)
5 to 6 cycles 99(72.3 %) 66(86.8 %)
Total treatment
time (days)




Note: SCCA squamous cell carcinoma, ACA adenocarcinoma
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parametrial boost was performed to a cumulative dose
of 56 Gy according to our institutional protocol.
Intracavitary Brachytherapy (ICBT)
ICBT was used in all patients. The tandem/ovoids
(Fletcher-Williamson “Asia-Pacific” model) or tandem/cy-
linder (in case of more than one-third vaginal involve-
ment) were used. Four applications were performed in all
Table 2 The 3-year local control, disease-free survival, metastasis-
free survivaland overall survival rates of cisplatin versus carboplatin
Parameters Cisplatin (N = 137) Carboplatin (N = 76) p-value
Local control 94.9 % 89.5 % 0.13
Disease-free survival 81.8 % 78.9 % 0.62
Metastasis-free
survival
83.9 % 86.8 % 0.56
Overall survival 86.1 % 89.5 % 0.48
Fig. 2 Kaplan-Meier curves showing (a) disease-free survival rate and (b) overall survival rates of cisplatin (continuous line) versus carboplatin (dotted line)
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patients. The first BT application was generally planned
after the fourth week of WPRT with 1–2 fractions per
week. The total dose of 24–28 Gy in 4 fractions was
prescribed.
Combined chemo-radiation (CCRT)
All enrolled patients were assigned to receive cisplatin
or carboplatin after study enrollment. CCRT with weekly
cisplatin at a dose of 40 mg/m2 or weekly carboplatin at
a dose of area under curve (AUC) equal to 2 for a
maximum of six courses was given to all patients with
sufficient kidney and bone marrow function during the
EBRT. For the dosing of carboplatin, glomerular filtra-
tion rate (GFR) was calculated from serum creatinine,
age and body weight and the dose of AUC 2 was
calculated from the GFR by using Calvert’s formula [17].
The maximum dose of chemotherapy for each cycle was
70 mg of cisplatin and 200 mg of carboplatin. Complete
blood counts and renal function tests (serum blood urea
nitrogen and creatinine) were evaluated weekly before
consideration of chemotherapy. The dose of chemotherapy
was modified according to a weekly assessment of creatin-
ine clearance prior to each applied dose. Chemotherapy
was interrupted when creatinine clearance was less than
40 ml/min for cisplatin and it was stopped when creatinine
clearance was less than 30 ng/ml (Fig. 1).
Study end point
The primary end point was overall survival rate. Other
treatment results and toxicies were evacuate as second-
ary end point. All events were measured from the date
of randomization to the date of their occurrence or the
the date of the last follow-up visit. Toxicity were graded
according to the Common Terminology Criterias of
Adverse Events (CTCAE) version 3.0 [18].
Follow-up program
After treatment was completed, patients were appointed
to visits including vaginal examination (PV exam) in a
follow-up program. The follow-up schedule included visits
every 3–4 months in the first 2 years after treatment,
every 6 months in the 3rd to 5th year and then annually
after the 5th year. A vaginal examination was performed to
evaluate the disease status according to the World Health
Organization (WHO) criteria [19]. Further investiga-
tions to identify disease progression were performed
when indicated by clinical findings. Late toxicities
were evaluated according to the Radiation Therapy
Oncology Group/European Organization of Research
and Treatment of Cancer (RTOG/EORTC) late tox-
icity criteria [20]. CTCAE version 3.0 was only used
to evaluate vaginal obstruction.
Statistical analysis
Study enrollment was planned for 5 years and performed
from 2009–2013. Overall survival (OS), metastasis-free
survival (MFS), disease-free survival (DFS) and local
control (LC) rates were evaluated using Kaplan-Meier
estimates and compared using the log-rank test. Clinical
and patient factors were compared using Pearson’s chi-
squared, Mann–Whitney-U or Independent-Samples T
test as appropriate. All statistical analyses were per-
formed using the SPSS version 17.00 (IBM company
software, Chicago, Illinois, USA).
Results
Patient characteristics
Forty-two patients were excluded from analysis process
due to incomplete treatment schedule (31 patients) and
addition of neoadjuvnat chemotherapy (11 patients).
Thus, 213 patients could be evaluated. One hundred thirty
seven patients received weekly cisplatin and 76 patients
weekly carboplatin. In the whole group, the mean age was
52.4 years (21–70 years). The mean maximal diameter of
primary lesion was 4.4 cm (2–9 cm). Stage IIB was the
most common in patients (134 patients). 180 patients
(84.5 %) had squamous cell carcinoma (SCCA) and the
most common grade was moderately differentiated
(58.7 %). The median follow-up time was 43 months
(6–69 months) and the mean total treatment time
was 56.5 days (34–173 days). All patient characteris-
tics were shown in Table 1.
Treatment results
The 3-year local control, disease-free survival, metastasis-
free survival and overall survival rates were 93 %, 80.8, 85
and 87.3 %, respectively. 33 patients (15.5 %) developed
distant metastasis and 18 patients (8.4 %) developed lymph
Table 3 The 3- year local control rate, disease-free survival rate,
metastasis-free survival and overall survival rate of cisplatin versus
carboplatin according to stage
Stage IIB Cisplatin (N = 137) Carboplatin (N = 76) p-value
Local control 96.7 % 95.3 % 0.68
Disease-free survival 86.8 % 86 % 0.78
Metastasis-free
survival
87.9 % 88.4 % 0.98
Overall survival 89 % 93 % 0.5
Stage IIIB Cisplatin (N = 137) Carboplatin (N = 76) p-value
Local control 93.2 % 83.9 % 0.22
Disease-free survival 75 % 71 % 0.88
Metastasis-free
survival
77.3 % 83.9 % 0.44
Overall survival 84.1 % 84 % 0.99
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node metastases. No statistical significance in terms of
local control, disease-free survival, metastasis-free survival
and overall survival rates was observed between the
cisplatin and carboplatin cohorts. All data are detailed in
Table 2 and Fig. 2.
Analyses were performed by stratification on stage IIB
(135 patients) and stage IIIB (74 patients) which com-
posed the largest populations in these groups. In stage
IIB, the local control, disease-free survival, metastasis-
free survival and overall survival rates were 96.3, 86.6,
88.1, and 90.3 %, respectively. In stage IIIB, the local
control, disease-free survival, metastasis-free survival
and overall survival rates were 89.3, 73.3, 80 and 84 %,
respectively. No statistically significant difference between
both study groups in terms of local control, disease-free
survival and overall survival rates could be identified
stratified by stage. All data of stage IIB and IIIB are shown
in Table 3 and Figs. 3 and 4.
Fig. 3 Kaplan-Meier curves showing (a) disease-free survival rate and (b) overall survival rates of cisplatin (continuous line) versus carboplatin (dotted
line) in stage IIB of cervical carcinoma
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Toxicity profiles
The most common toxicities were anemia (18.8 % or 40
patients) for acute toxicity and gastrointestinal side
effects (14.6 % or 31 patients) for late toxicity. In terms
of acute toxicity, patients who received cisplatin devel-
oped higher rates of anemia, neutropenia and renal
toxicity than the patients in the carboplatin group. No
difference in thrombocytopenia, radiation dermatitis,
proctitis or cystitis was observed. All data of acute
toxicity are shown in Table 4.
In terms of late toxicity, no statistically significant
difference between the cisplatin and carboplatin groups
for gastrointestinal, genitourinary, dermatological or
vaginal toxicity was found. All data of late toxicity strati-
fied by study group are shown in Table 5.
Discussion
The present study reports outcomes following CCRT
using carboplatin in comparison to cisplatin for locally
advanced carcinoma of cervix uteri in good general
Fig. 4 Kaplan-Meier curves showing (a) disease-free survival rate and (b) overall survival rates of cisplatin (continuous line) versus carboplatin (dotted
line) in stage IIIB of cervical carcinoma
Tharavichitkul et al. BMC Cancer  (2016) 16:501 Page 6 of 9
condition. Our data show comparable results of carbo-
platin versus cisplatin in CCRT in terms of local control,
disease-free survival, metastasis-free survival and overall
survival rates with p-value of 0.13, 0.62, 0.56 and 0.48,
respectively. The present results are in concordance with
the studies of Nam et al. and Au-Yeung et al. in terms of
survival rates [9, 21]. In stage IIB, local control, disease-
free survival, metastasis-free survival and overall survival
rates between group I and group II were not statistically
significant. In stage IIIB, no statistical significance in all
endpoints could be observed as well.
In addition, the patient characteristics of both groups
were well balanced without statistically significant
differences in age, stage, maximal diameter, grade, hist-
ology, follow-up time and total treatment time although
the mean age of group II (carboplatin) was slightly
higher than group I (cisplatin) (53.8 years vs. 51.6 years;
p = 0.051). Group II patients had a higher compliance
rate (received > 4 cycles) than group I (86.8 % vs. 72.3 %;
p = 0.02) and this finding matched the results of Nam et
al. who showed that the numbers of received cycles of
carboRT was higher than cisRT (7.5 versus 6; p < 0.001)
[21]. The main difference which was found in the
present study is the acute toxicity. Cisplatin signifi-
cantly caused more anemia (p = 0.026), neutropenia
(p = 0.044) and nephrotoxicity (p = 0.031) than carbo-
platin while other parameters were equal. However,
no statistical significance between the two groups in
terms of late dermatotoxicities, gastrointestinal toxic-
ities, genitourinary toxicities and vaginal toxicities
were observed.
Carboplatin, either in combination or as a single-agent,
may offer advantages in patients aged >75 years and in
Table 4 Acute toxicity of cisplatin versus carboplatin
Acute toxicity cisplatin (N = 137) carboplatin (N = 76) P-value
Anemia 0.026
Grade 0 87(63.5 %) 57(75.0 %)
Grade 1 19(13.9 %) 10(13.2 %)
Grade 2 28(20.7 %) 5(6.6 %)
Grade 3 3(2.2 %) 4(5.3 %)
Neutropenia 0.044
Grade 0 84(61.3 %) 57(75 %)
Grade 1 25(18.2 %) 14(18.4 %)
Grade 2 25(18.2 %) 5(6.6 %)
Grade 3 3(2.2 %) 0
Thrombocytopenia 0.392
Grade 0 128(93.4 %) 72(94.7 %)
Grade 1 4(2.9 %) 0
Grade 2 4(2.9 %) 4(5.3 %)
Grade 3 1(0.7 %) 0
Renal toxicity 0.031
Grade 0 112(81.8 %) 73(96.5 %)
Grade 1 8(5.8 %) 1(1.3 %)
Grade 2 10(7.3 %) 1(1.3 %)
Grade 3 7(5.1 %) 1(1.3 %)
Skin toxicity 0.45
Grade 0 139(94.9 %) 75(98.7 %)
Grade 1 4(2.9 %) 1(1.3 %)
Grade 2 3(2.2 %) 0
Proctitis 0.94
Grade 0 122(89.1 %) 67(88.2 %)
Grade 1 9(6.6 %) 6(7.9 %)
Grade 2 6(4.4 %) 3(3.9 %)
Cystitis 0.066
Grade 0 130(94.9 %) 67(88.2 %)
Grade 1 7(5.1 %) 7(9.2 %)
Grade 2 0 2(2.6 %)
Table 5 Late toxicity profiles of cisplatin versus carboplatin
Late toxicity cisplatin (N = 137) carboplatin (N = 76) p-value
Chronic GI 0.331
Grade 0 103(75.2 %) 63(82.9 %)
Grade 1 13(9.5 %) 3(3.9 %)
Grade 2 15(10.9 %) 5(6.6 %)
Grade 3 2(1.5 %) 3(3.9 %)
Grade 4 4(2.9 %) 2(2.6 %)
Chronic GU 0.206
Grade 0 122(89.1 %) 69(90.8 %)
Grade 1 6(4.4 %) 1(1.3 %)
Grade 2 6(4.4 %) 1(1.3 %)
Grade 3 1(0.7 %) 3(3.9 %)
Grade 4 2(1.5 %) 2(2.6 %)
Chronic skin 1.00
Grade 0 135(98.5 %) 75(98.7 %)
Grade 1 1(0.7 %) 0
Grade 2 1(0.7 %) 1(1.3 %)
Subcutaneous tissue 0.849
Grade 0 117(85.4 %) 65(85.5 %)
Grade 1 13(9.5 %) 6(7.9 %)
Grade 2 7(5.1 %) 5(6.6 %)
Vaginal obstruction 0.281
Grade 0 101(73.7 %) 58(76.3 %)
Grade 1 17(12.4 %) 9(11.8 %)
Grade 2 18(13.1 %) 6(7.9 %)
Grade 3 1(0.7 %) 3(3.9 %)
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those with decreased performance status [22]. Many stud-
ies reported the use of weekly carboplatin in combination
with WPRT in the treatment of locally advanced cervical
cancer. When we compared the carboplatin group with
other studies, it showed comparable results (Table 6).
This study has some limitations. Firstly, this study is
observational study. This study was firstly designed as
non-inferiority study. The sample size for this study is
determined to compare the 5-year survival rate and at
least 223 patients in each arm were required to provide
at least 80 % power to be able to detect this difference in
5-year survival rate between the study arms for a
two-sided test with alpha = 0.05. Unfortunately, the
enrollment has problem due to poor accrual. Sec-
ondly, 42 patients had to be excluded from analysis.
Eleven patients received neo-adjuvant chemotherapy
and 31 patients had incomplete treatment.
Despite the mentioned limitations, this study showed
similar results in terms of local control, disease-free sur-
vival, metastasis-free survival and overall survival rate in
both study arms along with a better compliance rate and
lower acute toxicity in terms of neutropenia and nephro-
toxicity in the carboplatin cohort. This study results sup-
port the use of carboplatin in CCRT for locally advanced
carcinoma of cervix uteri in patients with good general
conditions. Moreover, the administration of carboplatin
is generally easier than cisplatin. In our routine practice,
the whole chemotherapy process per cycle lasts three
hours for carboplatin versus six hours for cisplatin. In
the context of a high-volume, high-workload institute,
carboplatin-based CCRT is easier to manage.
Conclusions
The use of carboplatin in combination with radiation
therapy is comparable to cisplatin in terms of treatment
outcomes. In addition, the compliance in the carboplatin
arm was better and the observed acute toxicity in terms
of anemia, neutropenia and neprotoxicity was lower in
the carboplatin versus cisplatin group. The present study
results encourage the use of carboplatin in the treatment
of locally advanced cervix carcinoma in patients with
good general condition.
Abbreviations
ACA, adenocarcinoma; AUC, area under curve; CCRT, combined chemoradiation;
CTCAE, common terminology criterias of adverse events; DFS, disease-free
survival; FIGO, international federation of gynecology and obstetrics; GFR,
glomerular filtration rate; GI, gastrointestinal; GU, genitourinary; ICBT, intracavitary
brachytherapy; OS, overall survival; PFS, progression-free survival; RTOG/EORTC,
Radiation Therapy Oncology Group/European Organization of Research and
Table 6 Studies of carboplatin in CCRT for locally advanced cervical cancer
Studies N Stage Treatment results Late Toxicities
Cetina et al. [11] 85 (high risk of poor
renal dysfunction)











Katanyoo et al. [13] 148 IIB 50.7 % 2-years PFS 75.1 % Grade 3–4 GI 10.1 %
IIIB 48.0 % 5-years PFS 63 % Grade 3–4 GU 0.7 %
IVA 1.3 % 2-years OS 81.9 %
5-years OS 63.5 %
Sangkittipaiboon et al. [14] 105 IIB 83 5-years DFS 52.38 % Grade 3–4 GI 3.2 %
III, 19 5-years OS 56.19 % Grade 3–4 GU 0 %
IVA 3
Our study 76 IIB 56.6 % 3-years DFS 78.9 % Grade 3–4 GI 6.5 %
IIIA 2.6 % 3-years OS 89.5 % Grade 3–4 GU 6.5 %
IIIB 40.8 %
Note: PFS progression-free survival, DFS Disease-free survival, OS overall survival, GI gastrointestinal, GU genitourinary
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Treatment of Cancer; SCCA, squamous cell carcinoma; WPRT, whole pelvic
radiotherapy
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